Organization | Helse Fonna

Helse Fonna Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Haugesund Norway (2002)

Organization Overview

First Clinical Trial

2003

NCT00553293

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

arvid.rongve@helse-fonna.no | Head of Research Department at Helse Finna HF | Helse Fonna | Helse Fonna HF

Active Ingredients

Drugs in Phase 4 Trials (10)

ephedrine (1 trial)

epinephrine (levophed) (1 trial)

follitropin alfa (1 trial)

levobupivacaine (chirocaine) (1 trial)

lutropin alpha (luveris) (1 trial)

norepinephrine (levophed) (1 trial)

phenylephrine (Prefrin) (1 trial)

propofol (diprivan) (2 trials)

remifentanil (ultiva) (2 trials)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (6)

ambroxol (1 trial)

atezolizumab (tecentriq) (1 trial)

bendamustine (treanda) (1 trial)

rituximab (rituxan) (1 trial)

sargramostim (leukine) (1 trial)

uv1 vaccine (1 trial)

Drugs in Other Trials (2)

human fecal microbiota (Reybota) (2 trials)

lansoprazole (prevacid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia, Hemolytic (Phase 2)

Anemia, Hemolytic, Autoimmune (Phase 2)

Cervical Intraepithelial Neoplasia (Phase 4)

Dementia (Phase 2)

Hemolysis (Phase 2)

Infertility (Phase 4)

Lewy Body Disease (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 18